Clinical trial · Interventional
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
Light Therapy to Prevent Frailty in Older Men With Prostate Cancer on Hormonal Therapy: A Pilot RCT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot trial studies how well systemic light exposure works in preventing frailty in older patients with prostate cancer on hormonal therapy. Hormone therapy causes many symptoms of frailty in older men including fatigue, slower time to walk a specified distance, reduced activity levels, loss of lean muscle, and muscle weakness. It is not yet known if systemic light exposure may reduce frailty in older prostate cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Actigraph | Device | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
| Systematic Light Exposure | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (BWL)
- description
- Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
- interventionNames
- Device: Actigraph
- Other: Questionnaire Administration
- Procedure: Systematic Light Exposure
- type
- EXPERIMENTAL
- label
- Arm II (DWL)
- description
- Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
- interventionNames
- Device: Actigraph
- Other: Questionnaire Administration
- Procedure: Systematic Light Exposure
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate cancer (PC) patients who are starting androgen deprivation therapy (ADT), abiraterone, or enzalutamide with plans to continue for at least six months with minimal evidence of disease burden in accordance with current standards of care. * A life expectancy of 6 months or longer. * All subjects must have the ability to understand and the willingness to sign a written or electronic informed consent. Exclusion Criteria: * Significant pre-existing frailty precluding completion of baseline assessments. * Other active malignancies * Previous use of radiation therapy within the year prior to consent. * Widely metastatic disease. * Confounding serious medical illnesses which causes frailty. * Severe sleep disorders. * Eye diseases which limit the ability of light to be processed. * Severe psychological impairment. * Current employment in night shift work. * Previous use of light therapy to alleviate fatigue or depressive symptoms. * Secondary cancer diagnosis within the past 5 years. * Plans to travel across meridians during treatment. * Uncontrolled illness including ongoing or active infection in disease status patients.
References
Publications (0)
Data not yet available